A clinical trial involving bivalirudin was registered with a status update recorded on November 12, 2026. The trial is titled The MInimizing RIsk of CLotting Events Trial, identified as NCT07930429. Its current status is listed as not yet recruiting. The phase is listed as NA. No participants have been reported as enrolled based on this status. No outcomes, efficacy data, or safety findings have been reported as part of this update. The listing reflects only the administrative status of the trial at this stage. Bivalirudin remains an approved compound according to current regulatory status. Further details about the trial design, timeline, or recruitment criteria are not included in this update. As the trial has not yet begun recruiting, no interim or final results are available for review. This brief reflects only the information provided in the trial registration record as of the stated date. Readers interested in the broader context of bivalirudin, including its approved uses and background, can consult the compound overview for additional information.
Bivalirudin Trial "MInimizing RIsk of CLotting Events" Registered, Not Yet Recruiting
See the full bivalirudin overview
Source: https://clinicaltrials.gov/study/NCT07930429